Depicting Medullary Thyroid Cancer Recurrence: the Past and the Future of Nuclear Medicine Imaging

Context: inherited and sporadic medullary thyroid cancer (mtc) is an uncommon and medically challenging malignancy. even if the extent of initial surgery is deemed adequate, the recurrence rate remains high, up to 50% in most series. measurement of serum calcitonin is important in the follow-up of patients with mtc, and reliably reflects the existence of the disease. evidence acquisition: there is no single sensitive diagnostic imaging method to reveal all mtc recurrences or metastases. conventional morphologic imaging methods (u/s, ct, and mri) and several methods of nuclear medicine have been used for this purpose with variable accuracy. results: the main role of nuclear medicine imaging is the detection of residual or recurrent tumor in the postoperative follow-up. in this review we present the radiopharmaceuticals used in the diagnosis of mtc recurrence, and comparison among them. conclusions: the most used radiopharmaceuticals labelled with γ emitters are: metaiodobenzylguanidine (mibg), labelled with 131i or 123i, 111in-pentetreotide (octreoscan), 99mtc-pentavalent dimercaptosuccinic acid (99mtc(v)-dmsa), and 99mtc-edda/hynic-tyr3-octreotide ( tektrotyd). the radiopharmaceuticals labelled with a positron-emitting radionuclide (β+), suitable for positron emission tomography (pet) imaging are: 18f-fluorodeoxyglucose (18f-fdg), 18f-fluorodihydroxyphenylalanine (18f-dopa), and 68ga-labelled somatostatin analogues (68ga-dotatate or dotatoc).